An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.
High unmet needs are one of the primary drivers of market growth. The need for the development of effective drugs with lesser side-effects is rapidly rising in the market.
Moreover, the initiatives from the governments of various countries across the globe towards R&D activities and numerous marketing approvals of these drugs have also influenced the orphan drugs market growth. Furthermore, the rising occurrences of rare diseases with the mounting awareness among the population and larger life expectancy numbers have accelerated the global orphan drug market to grow higher.
In 2019, the market size of Orphan Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Orphan Drugs.
This report studies the global market size of Orphan Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Orphan Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Novartis
Bristol-Myers Squibb
Celgene
Roche
Pfizer
Sanofi
Alexion Pharmaceuticals
Eli Lilly
Novo Nordisk
AstraZeneca
Eisai
Daiichi Sankyo
Bayer
GlaxoSmithKline
Merck
Johnson & Johnson
Biogen
Shire
Amgen
Market Segment by Product Type
Oncology
Gastrointestinal
Pulmonary
Neurology
Hematology
Cardio-vascular
Metabolic disorders
Endocrinology
Infectious diseases
Others
Market Segment by Application
Hospital Pharmacies
Speciality Pharmacies
Retail pharmacies
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Orphan Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Orphan Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Orphan Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Summary:
Get latest Market Research Reports on Orphan Drugs. Industry analysis & Market Report on Orphan Drugs is a syndicated market report, published as Global (United States, European Union and China) Orphan Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Orphan Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.